TNF and rheumatoid arthritis: Together, these results suggest that pro-Infliximab may not affect systemic TNFα during circulation thoroughly, thus keeping its biological functions and preventing the undesirable blocking effect of TNF-dependent host defense mechanism, thereby maintaining part of host immunity during RA treatment.